FRANKFURT (Reuters) – Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given at longer intervals but its current focus on other disease areas would provide for sales growth well into the 2030s.
“We are not really reliant on the obesity wave. We feel like we can grow robustly through the end of this decade and into the next decade with the platforms that we have,” CEO Vas Narasimhan said in a media call after the release of quarterly results.
(Reporting by Ludwig Burger, Editing by Rachel More)
Comments